These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 6105772)

  • 1. Dopamine-sensitive adenylate cyclase and dopamine/neuroleptic receptor binding: effect of neuroleptic drugs.
    Marshall AM; Mishra RK
    Adv Biochem Psychopharmacol; 1980; 24():153-7. PubMed ID: 6105772
    [No Abstract]   [Full Text] [Related]  

  • 2. Dopamine-sensitive adenylate cyclase and receptor binding activities after acute and chronic neuroleptic drug treatment.
    Clement-Cormier Y
    Adv Biochem Psychopharmacol; 1980; 24():103-11. PubMed ID: 6105768
    [No Abstract]   [Full Text] [Related]  

  • 3. Neuroleptic/dopamine receptors: elevation and reversal.
    List S; Seeman P
    Adv Biochem Psychopharmacol; 1980; 24():95-101. PubMed ID: 6105811
    [No Abstract]   [Full Text] [Related]  

  • 4. Dopamine receptor binding of a novel dibenzodioxazocine derivative, EGYT-2509.
    Gyüre K; Szentendrei T; Kanyicska B; Fekete MI; Rónai AZ
    Pol J Pharmacol Pharm; 1985; 37(3):253-61. PubMed ID: 2866498
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Participation of an endogenous Ca++-blinding protein activator in the development of drug-induced supersensitivity of striatal dopamine receptors.
    Gnegy M; Uzunov P; Costa E
    J Pharmacol Exp Ther; 1977 Sep; 202(3):558-64. PubMed ID: 19618
    [No Abstract]   [Full Text] [Related]  

  • 6. [Effect of carbidine on the dopamine and serotonin receptors of the central nervous system].
    Zharkovskiĭ AM; Klassen NE; Zharkovskiĭ TA
    Biull Eksp Biol Med; 1985 Jun; 99(6):700-2. PubMed ID: 2861866
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Similarities and dissimilarities between dopamine and neuroleptic receptors: further evidence for type 1 and type 2 dopamine receptors in the CNS.
    Spano PF; Memo M; Govoni S; Trabucchi M
    Adv Biochem Psychopharmacol; 1980; 24():113-21. PubMed ID: 6105769
    [No Abstract]   [Full Text] [Related]  

  • 8. Central nervous system dopamine receptors.
    Creese I
    Adv Biochem Psychopharmacol; 1980; 21():235-42. PubMed ID: 6103649
    [No Abstract]   [Full Text] [Related]  

  • 9. Long-term adaptive changes in striatal dopamine function in response to chronic neuroleptic intake in rats.
    Jenner P; Kerwin R; Rupniak NM; Murugaiah K; Hall MD; Fleminger S; Marsden CD
    J Neural Transm Suppl; 1983; 18():205-12. PubMed ID: 6135741
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sustained gamma-aminobutyric acid receptor stimulation and chronic neuroleptic effects.
    Lloyd KG; Worms P
    Adv Biochem Psychopharmacol; 1980; 24():253-8. PubMed ID: 6105780
    [No Abstract]   [Full Text] [Related]  

  • 11. Changes in apomorphine-induced stereotypy as a result of subacute neuroleptic treatment correlates with increased D-2 receptors, but not with increases in D-1 receptors.
    Fleminger S; Rupniak NM; Hall MD; Jenner P; Marsden CD
    Biochem Pharmacol; 1983 Oct; 32(19):2921-7. PubMed ID: 6138043
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interactions of neurotensin with brain dopamine systems: biochemical and behavioral studies.
    Nemeroff CB; Luttinger D; Hernandez DE; Mailman RB; Mason GA; Davis SD; Widerlöv E; Frye GD; Kilts CA; Beaumont K; Breese GR; Prange AJ
    J Pharmacol Exp Ther; 1983 May; 225(2):337-45. PubMed ID: 6682440
    [TBL] [Abstract][Full Text] [Related]  

  • 13. No evidence for increased dopamine receptor binding in superresponsive mice after a single dose of neuroleptics.
    Hyttel J
    Adv Biochem Psychopharmacol; 1980; 24():167-73. PubMed ID: 6105773
    [No Abstract]   [Full Text] [Related]  

  • 14. Biochemical characteristics of D1 dopamine receptors: relationship to behavior and schizophrenia.
    Creese I; Hess EJ
    Clin Neuropharmacol; 1986; 9 Suppl 4():14-6. PubMed ID: 2882838
    [No Abstract]   [Full Text] [Related]  

  • 15. Neuroleptic activity of the 5-aryltetrahydro-gamma-carboline series. Conformational requirements for interaction with central dopamine receptors.
    Harbert CA; Plattner JJ; Welch WM; Weissman A; Koe BK
    Mol Pharmacol; 1980 Jan; 17(1):38-42. PubMed ID: 6104285
    [No Abstract]   [Full Text] [Related]  

  • 16. Differential sensitivity to neuroleptic drugs of cerebral dopamine receptors following chronic treatment of rats with trifluoperazine.
    Dawbarn D; Pycock C
    Eur J Pharmacol; 1981 May; 71(2-3):233-45. PubMed ID: 6113967
    [No Abstract]   [Full Text] [Related]  

  • 17. N-oxides of phenothiazine antipsychotics: effects on in vivo and in vitro estimates of dopaminergic function.
    Lewis MH; Widerlöv E; Knight DL; Kilts CD; Mailman RB
    J Pharmacol Exp Ther; 1983 Jun; 225(3):539-45. PubMed ID: 6134814
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Further evidence for the existence of multiple receptors for dopamine in the central nervous system.
    Iversen LL; Quik M; Emson PC; Dowling JE; Watling KJ
    Adv Biochem Psychopharmacol; 1980; 21():193-202. PubMed ID: 6103646
    [No Abstract]   [Full Text] [Related]  

  • 19. Ziprasidone (CP-88,059): a new antipsychotic with combined dopamine and serotonin receptor antagonist activity.
    Seeger TF; Seymour PA; Schmidt AW; Zorn SH; Schulz DW; Lebel LA; McLean S; Guanowsky V; Howard HR; Lowe JA
    J Pharmacol Exp Ther; 1995 Oct; 275(1):101-13. PubMed ID: 7562537
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Action of etmozin and ethacizin on dopaminergic adenylate cyclase of the striate system of the brain].
    Baldenkov GN; Ratner EI; Rozenshtraukh LV; Tkachuk VA
    Biull Eksp Biol Med; 1984 Oct; 98(10):448-50. PubMed ID: 6149776
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.